Pfizer and BridgeBio Secure Patent Win: Key Biotech Developments Today
Italian pharma giant Chiesi acquires KalVista Therapeutics for $1.9 billion, adding a rare-disease treatment to its portfolio. Meanwhile, major biotec...
Xeber.world
hereditary angioedema
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Astellas Revives XLMTM Gene Therapy Trial After Patient Deaths: Key Biotech Updates
Astellas is reentering clinical trials for its next-generation XLMTM gene therapy following patient deaths. Eli Lilly acquires Ajax Therapeutics for u...
Intellia’s CRISPR Gene Therapy for Rare Disease Advances in Phase 3 Trial, Sun Pharma to Acquire Organon for $11.75B
Intellia Therapeutics reported that a single dose of its CRISPR-based gene editing therapy, lonvo-z, dramatically reduced swelling attacks in a Phase...
Intellia's CRISPR Gene Therapy Lonvo-z Slashes Swelling Attacks in Rare Disease Trial, Paving Way for Approval
Intellia Therapeutics announced Monday that a single dose of its CRISPR-based gene editing treatment, lonvo-z, dramatically reduced swelling attacks i...